Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

Published:2019-01 Issue:1 Volume:6 Page:e38-e47
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Davids Matthew S,Kim Haesook T,Nicotra Alyssa,Savell Alexandra,Francoeur Karen,Hellman Jeffrey M,Bazemore Josie,Miskin Hari P,Sportelli Peter,Stampleman Laura,Maegawa Rodrigo,Rueter Jens,Boruchov Adam M,Arnason Jon E,Jacobson Caron A,Jacobsen Eric D,Fisher David C,Brown Jennifer R

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Targeting BTK with ibrutinib in relapsed chronic lymphcytic leukemia;Byrd;N Engl J Med,2013

2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

3. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib;Woyach;N Engl J Med,2014

4. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia;Woyach;J Clin Oncol,2017

5. Postibrutinib outcomes in patients with mantle cell lymphoma;Martin;Blood,2016

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

2. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06

3. Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications;European Journal of Medicinal Chemistry;2024-06

4. Management of relapsed/refractory mantle cell lymphoma;Leukemia & Lymphoma;2024-04-18

5. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas;British Journal of Haematology;2024-03-19